Gender and age differences in the risk of allergic reactions following the Pfizer-BioNTech COVID-19 and AstraZeneca vaccine using skin prick test and intradermal test among patients with high risk for hypersensitivity.

IF 2.1 4区 医学 Q3 ALLERGY
Allergologia et immunopathologia Pub Date : 2025-09-01 eCollection Date: 2025-01-01 DOI:10.15586/aei.v53i5.1369
Leonora Svarça, Sonja Bojadzieva, Premtim Rashiti, Albiona Rashiti-Bytyçi, Diar Kabashi
{"title":"Gender and age differences in the risk of allergic reactions following the Pfizer-BioNTech COVID-19 and AstraZeneca vaccine using skin prick test and intradermal test among patients with high risk for hypersensitivity.","authors":"Leonora Svarça, Sonja Bojadzieva, Premtim Rashiti, Albiona Rashiti-Bytyçi, Diar Kabashi","doi":"10.15586/aei.v53i5.1369","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to assess the association between allergic reactions after COVID-19 vaccination and the history of high-risk allergy, individual predisposing factors such as age and gender, and COVID-19 vaccine type.</p><p><strong>Materials and methods: </strong>This retrospective cohort study included 234 adult patients (18 years old and above) who underwent a COVID-19 vaccine allergy test up until February 2023 in a Clinic of Allergy and Clinical Immunology in the University Clinical Center of Kosovo. All patients suspected of allergy underwent skin testing: SPT (skin prick test) and IDT (intradermal test) using either an mRNA (ribonucleic messenger acid) vaccine (BNT162b2, Pfizer-BioNTech) and/or an adenoviral vector vaccine (AZD1222, AstraZeneca). Subsequent immunization was administered under careful medical observation.</p><p><strong>Results: </strong>Among the 234 patients with a high-risk allergy profile, several potential risk factors were identified, including a history of multiple allergies, previous anaphylaxis, and/or drug allergies. In our cohort, food allergies were reported by 20 patients (8.5%) and multiple drug allergies were reported by 118 patients (50.4%). Due to the retrospective nature of the study, we cannot establish causality. Therefore, older age and receipt of the Pfizer-BioNTech vaccine were found to be associated with increased allergic reactions after COVID-19 vaccination, while male gender was associated with decreased risk. Although previous allergic manifestations were common among those with reactions, they were not significantly associated with increased risk after adjustment for confounders. The absence of a control group consisting of vaccinated individuals without a high-risk allergy history limits the generalizability of our findings.</p><p><strong>Conclusions: </strong>Immediate allergic reactions to COVID-19 vaccines are rare but can be severe and reoccur. Findings suggest that gender and age-specific factors may influence the response to the vaccine. Nevertheless, COVID-19 vaccines remain a critical tool in preventing severe disease and controlling the ongoing pandemic.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 5","pages":"5-11"},"PeriodicalIF":2.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v53i5.1369","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The aim of this study was to assess the association between allergic reactions after COVID-19 vaccination and the history of high-risk allergy, individual predisposing factors such as age and gender, and COVID-19 vaccine type.

Materials and methods: This retrospective cohort study included 234 adult patients (18 years old and above) who underwent a COVID-19 vaccine allergy test up until February 2023 in a Clinic of Allergy and Clinical Immunology in the University Clinical Center of Kosovo. All patients suspected of allergy underwent skin testing: SPT (skin prick test) and IDT (intradermal test) using either an mRNA (ribonucleic messenger acid) vaccine (BNT162b2, Pfizer-BioNTech) and/or an adenoviral vector vaccine (AZD1222, AstraZeneca). Subsequent immunization was administered under careful medical observation.

Results: Among the 234 patients with a high-risk allergy profile, several potential risk factors were identified, including a history of multiple allergies, previous anaphylaxis, and/or drug allergies. In our cohort, food allergies were reported by 20 patients (8.5%) and multiple drug allergies were reported by 118 patients (50.4%). Due to the retrospective nature of the study, we cannot establish causality. Therefore, older age and receipt of the Pfizer-BioNTech vaccine were found to be associated with increased allergic reactions after COVID-19 vaccination, while male gender was associated with decreased risk. Although previous allergic manifestations were common among those with reactions, they were not significantly associated with increased risk after adjustment for confounders. The absence of a control group consisting of vaccinated individuals without a high-risk allergy history limits the generalizability of our findings.

Conclusions: Immediate allergic reactions to COVID-19 vaccines are rare but can be severe and reoccur. Findings suggest that gender and age-specific factors may influence the response to the vaccine. Nevertheless, COVID-19 vaccines remain a critical tool in preventing severe disease and controlling the ongoing pandemic.

使用皮肤点刺试验和皮内试验的高危过敏患者使用辉瑞- biontech COVID-19和阿斯利康疫苗后过敏反应风险的性别和年龄差异
目的:研究新冠肺炎疫苗接种后过敏反应与高危过敏史、年龄、性别等个体易感因素、新冠肺炎疫苗类型的关系。材料和方法:这项回顾性队列研究包括234名成年患者(18岁及以上),截至2023年2月,他们在科索沃大学临床中心的过敏和临床免疫学诊所接受了COVID-19疫苗过敏试验。所有疑似过敏的患者都进行了皮肤试验:SPT(皮肤点刺试验)和IDT(皮内试验),使用mRNA(核糖核酸信使酸)疫苗(BNT162b2,辉瑞- biontech)和/或腺病毒载体疫苗(AZD1222,阿斯利康)。随后的免疫接种在仔细的医学观察下进行。结果:在234例高危过敏患者中,确定了几个潜在的危险因素,包括多种过敏史、既往过敏反应和/或药物过敏。在我们的队列中,20例(8.5%)患者报告了食物过敏,118例(50.4%)患者报告了多种药物过敏。由于这项研究是回顾性的,我们无法确定因果关系。因此,年龄较大和接种了辉瑞- biontech疫苗与COVID-19疫苗接种后过敏反应增加有关,而男性与风险降低有关。虽然先前的过敏表现在有反应的患者中很常见,但在调整混杂因素后,它们与风险增加没有显著相关。缺乏由无高危过敏史的接种疫苗个体组成的对照组限制了我们研究结果的普遍性。结论:对COVID-19疫苗的立即过敏反应罕见,但可能严重并再次发生。研究结果表明,性别和年龄特异性因素可能影响对疫苗的反应。尽管如此,COVID-19疫苗仍然是预防严重疾病和控制当前大流行的关键工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
0.00%
发文量
131
审稿时长
6-12 weeks
期刊介绍: Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信